Joseph Regan

Joseph Regan has an extensive background in the innovation sector contributing over two decades of experience to the Bioenterprise Board. He brings an industrial operating perspective and deep venture capital expertise gained from within two of Canada’s largest firms. Thoughtful and perceptive, he’s had broad exposure to a myriad of innovative technologies and diverse business models, having served a range of roles from gestational CEO to Chairman.

Most recently, Joseph was Vice President, Investments at GrowthWorks Capital where he was the most tenured investment team member and achieved top quartile North American Venture Capital Fund IRR performance. Previous to that, he held a similar position at Ventures West, where he served his venture apprenticeship. He entered venture capital from industry, having worked at Syntex Corporation (acquired by Hoffmann-La Roche Limited) where he distinguished himself as President’s Best for outstanding accomplishment.

Joseph has directly invested over one hundred million dollars and served as a member of the Board of Directors of over thirty companies. He has utilized persuasiveness and enthusiasm to navigate the human dynamic of investee evolution. Continual efforts that focused on performance and strategy assisted his investees in raising in excess of eight hundred million dollars. Regarded as a valuable Board contributor, Joseph brings a voice of reason having negotiated countless financial and strategic agreements. Notable Agri-Tech transactions include Targeted Growth Inc. (two multi-national agricultural biotechnology conglomerate partnerships), Sustainable Oils Inc. (JV with Green Earth Fuels), Matrix Genetics Inc. (global petro-chemical conglomerate partnership), and MCN BioProducts Inc. (acquired by Bunge Limited). Other select transactions include Cytochroma Inc. (Mitsubishi Tanabe Pharmaceutical Company global alliance, subsequently acquired by OPKO Health, Inc.), Ambit Biosciences Corporation (Astellas Pharma Inc. global partnership with subsequent IPO - NASDAQ:AMBI), GeminX Pharmaceuticals Inc. (acquired by Cephalon Inc., now owned by Teva Pharmaceuticals, Inc.), and Aegera Therapeutics Inc. (partnered with Human Genome Sciences Inc.).

Joseph has an Honours BSc (with distinction) from the University of Guelph, having earned several academic scholarships, as well as leading the Men’s Soccer team to the CIAU National Championship. He was also nominated for The W.F. Mitchell Sportsman Award for recognition of leadership excellence. Joseph completed his education earning a MBA (Dean's List) from McMaster University.

With his common-sensical approach, Joseph is eager to deploy resources to accelerate the next wave of Agri-Tech innovation and value creation.